Even application of highly specific inhibitors of BET proteins (iBETs) [11,12] that reversibly bind the bromodomains of Bromodomain and Extra-Terminal motif (BET) proteins BRD2, BRD3, BRD4, and BRDT, and thereby prevent interactions between BET proteins and acetylated histones and transcription factors, is followed quite early by the development of high-grade resistance, toxicities at high iBET dosages and a relapse of tumor disease [13,14,15]. This evidence concerns the gene BRD3 and neoplasm.